NP 031112
Tideglusib
CAS: 865854-05-3
Molecular Formula: C19H14N2O2S
NP 031112 - Names and Identifiers
| Name | Tideglusib |
| Synonyms | NP-12 NP031112 NP 031112 NP-031112 TIDEGLUSIB Tideglusib Tideglusib(NP-031112) 4-Benzyl-2-(naphthalen-1-yl)-[1,2,4]thiadiazolidine-3,5-dione 1,2,4-Thiadiazolidine-3,5-dione, 2-(1-naphthalenyl)-4-(phenylmethyl)- |
| CAS | 865854-05-3 |
| EINECS | 640-411-8 |
| InChIKey | PMJIHLSCWIDGMD-UHFFFAOYSA-N |
NP 031112 - Physico-chemical Properties
| Molecular Formula | C19H14N2O2S |
| Molar Mass | 334.39 |
| Density | 1.393 |
| Melting Point | 148 - 150oC |
| Boling Point | 511.3±43.0 °C(Predicted) |
| Solubility | DMSO: >15mg/mL |
| Appearance | powder |
| Color | white to beige |
| pKa | -1.51±0.20(Predicted) |
| Storage Condition | 2-8°C |
| MDL | MFCD18633296 |
| Use | Tideglusib |
| In vitro study | Irreversible inhibition of Tideglusib by GSK-3 in human neuroblastoma cells and murine primary neurons reduces tau protein phosphorylation levels and prevents apoptosis. Tideglusib (2.5 μm) inhibits glutamate-induced activation of glial cells, evidence for this conclusion is a decrease in the expression levels of TNF-α and COX-2 in rat primary astrocytes or microglia. Tideglusib (2.5 μm) also has a potent protective effect on cortical neurons from glutamate-induced excitotoxicity, evidence for this conclusion is a significant reduction in the number of Annexin-V positive cells in rat primary astrocytes or microglia Tideglusib in human neuroblastoma cells and rat primary neurons irreversible inhibition of GSK-3 thereby reduces the level of tau phosphorylation and prevents apoptosis. Tideglusib (2.5 μm) inhibits glutamate-induced activation of glial cells, evidence for this conclusion is a decrease in the expression levels of TNF-α and COX-2 in rat primary astrocytes or microglia. Tideglusib (2.5 μm) also has a potent protective effect on cortical neurons from glutamate-induced excitotoxicity, evidence for this conclusion is a significant reduction in the number of Annexin-V positive cells in rat primary astrocytes or microglia |
| In vivo study | Tideglusib (50 mg/kg) injection into the hippocampus of adult male Wistar rats significantly reduced kainic acid-induced inflammatory responses and had a protective effect on damaged areas of the hippocampus. In APP/tau double transgenic mice, Tideglusib (200 mg/kg, P. O.) reduced tau phosphorylation, reduced amyloid deposition and plaque-associated astrocyte proliferation, protection of neurons in the entorhinal cortex and hippocampal CA1 region from death and prevention of memory loss Tideglusib (50 mg/kg) injection into the hippocampus of adult male Wistar rats can greatly reduce the inflammatory response induced by kainic acid and has a protective effect on the damaged area of the hippocampus. In APP/tau double transgenic mice, Tideglusib (200 mg/kg, P. O.) reduced tau phosphorylation, reduced amyloid deposition and plaque-associated astrocyte proliferation, protection of neurons in the entorhinal cortex and hippocampal CA1 region to prevent death and memory loss |
NP 031112 - Risk and Safety
| WGK Germany | 3 |
NP 031112 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.991 ml | 14.953 ml | 29.905 ml |
| 5 mM | 0.598 ml | 2.991 ml | 5.981 ml |
| 10 mM | 0.299 ml | 1.495 ml | 2.991 ml |
| 5 mM | 0.06 ml | 0.299 ml | 0.598 ml |
Last Update：2024-01-02 23:10:35
NP 031112 - Introduction
Tideglusib is a small organic molecule compound with the chemical name of N-(6-bromo-2-pyridyl)-2,6-difluoroaniline guanidino methanesulfonamide. It is a white or off-white crystalline solid, stable at room temperature. The molecular formula of Tideglusib is C19H14BrF2N3O3S, and the relative molecular mass is 491.3.
The primary use of Tideglusib is as a protein kinase C(PKC) inhibitor. PKC is a class of enzymes involved in biological processes such as signal transduction, cell proliferation and apoptosis. The inhibitory effect of Tideglusib can regulate the activity level of PKC, which has potential therapeutic effects on some neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
The method for preparing Tideglusib includes the reaction of N-(6-bromo-2-pyridyl) -2,6-difluoroaniline and ethyl methanesulfonate, it is then converted to the target product of Tideglusib by a series of chemical reactions. The preparation process requires control of temperature and reaction conditions to ensure high purity and yield of the product.
Regarding the safety information of Tideglusib, according to existing research, it is usually relatively safe at recommend doses. However, for any chemical substance, the relevant safety data sheet and instructions should be carefully read before use, and the instructions for use should be strictly followed. When using or handling Tideglusib, care should be taken to avoid contact with skin and eyes and to ensure good ventilation conditions. If any symptoms of discomfort or intoxication appear, seek medical assistance immediately. In addition, because Tideglusib is a laboratory-grade chemical, its clinical safety and effectiveness still need further research and verification.
The primary use of Tideglusib is as a protein kinase C(PKC) inhibitor. PKC is a class of enzymes involved in biological processes such as signal transduction, cell proliferation and apoptosis. The inhibitory effect of Tideglusib can regulate the activity level of PKC, which has potential therapeutic effects on some neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease.
The method for preparing Tideglusib includes the reaction of N-(6-bromo-2-pyridyl) -2,6-difluoroaniline and ethyl methanesulfonate, it is then converted to the target product of Tideglusib by a series of chemical reactions. The preparation process requires control of temperature and reaction conditions to ensure high purity and yield of the product.
Regarding the safety information of Tideglusib, according to existing research, it is usually relatively safe at recommend doses. However, for any chemical substance, the relevant safety data sheet and instructions should be carefully read before use, and the instructions for use should be strictly followed. When using or handling Tideglusib, care should be taken to avoid contact with skin and eyes and to ensure good ventilation conditions. If any symptoms of discomfort or intoxication appear, seek medical assistance immediately. In addition, because Tideglusib is a laboratory-grade chemical, its clinical safety and effectiveness still need further research and verification.
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Tideglusib Visit Supplier Webpage Request for quotationCAS: 865854-05-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Tideglusib Visit Supplier Webpage Request for quotationCAS: 865854-05-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History